Marshall Wace
SABS icon

Marshall Wace’s SAB Biotherapeutics SABS Stock Holding History

Marshall Wace’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.78M Buy
463,925
+227,465
+96% +$907K ﹤0.01% 1852
2025
Q4 		$884K Buy
+236,460
New +$778K ﹤0.01% 1997
2025
Q1 		– Sell
-459,168
Closed -$1.75M – 3033
2024
Q4 		$1.75M Hold
459,168
– – ﹤0.01% 1500
2024
Q3 		$1.24M Hold
459,168
– – ﹤0.01% 1560
2024
Q2 		$1.42M Hold
459,168
– – ﹤0.01% 1526
2024
Q1 		$2.08M Buy
459,168
+640
+0.1% +$3.52K ﹤0.01% 1348
2023
Q4 		$3.16M Buy
+458,528
New +$3.84M 0.01% 1064
2022
Q1 		– Sell
-50
Closed -$3K – 3928
2021
Q4 		$3K Buy
+50
New +$4.69K ﹤0.01% 3778

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace's SABS Position: Q1 2026 in Review

Marshall Wace increased its SAB Biotherapeutics (SABS) stake by 96% in Q1 2026, buying an estimated $907K and bringing the position to 463,925 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1852.

Marshall Wace first reported a position in SABS in Q4 2021 and has held it in 8 quarters since. The position peaked at $3.16M in Q4 2023. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Marshall Wace held 463,925 shares of SAB Biotherapeutics worth $1.78M as of Q1 2026.
  • Marshall Wace bought 227,465 SAB Biotherapeutics shares in Q1 2026, an estimated $907K.
  • SAB Biotherapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1852 holding.
  • Marshall Wace first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 8 quarters since.
  • Marshall Wace's SAB Biotherapeutics position peaked at $3.16M in Q4 2023.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.